BR0114030A - Método para preparação de células dendrìticas maduras, crioconservadas, prontas para uso, introduzidas ou não com antìgenos - Google Patents

Método para preparação de células dendrìticas maduras, crioconservadas, prontas para uso, introduzidas ou não com antìgenos

Info

Publication number
BR0114030A
BR0114030A BR0114030-2A BR0114030A BR0114030A BR 0114030 A BR0114030 A BR 0114030A BR 0114030 A BR0114030 A BR 0114030A BR 0114030 A BR0114030 A BR 0114030A
Authority
BR
Brazil
Prior art keywords
dendritic cells
ready
antigens
preparation
mature
Prior art date
Application number
BR0114030-2A
Other languages
English (en)
Inventor
Gerold Schuler
Beatrice Schuler-Thurner
Original Assignee
Gerold Schuler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gerold Schuler filed Critical Gerold Schuler
Publication of BR0114030A publication Critical patent/BR0114030A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4648—Bacterial antigens
    • A61K39/46482—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/185—Osteoprotegerin; Osteoclast differentiation factor (ODF, RANKL)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)

Abstract

"MéTODO PARA PREPARAçãO DE CéLULAS DENDRìTICAS MADURAS, CRIOCONSERVADAS, PRONTAS PARA USO, INTRODUZIDAS OU NãO COM ANTìGENOS". A invenção se refere a um método para produção de células dendríticas maduras, crioconservadas, prontas para uso, especialmente para produção de uma vacina que contém tais células dendríticas, em que as células dendríticas imaturas são cultivadas na presença de adequados estimulantes de maturação e as células dendríticas maduras assim obtidas, são congeladas. As células dendríticas podem ser introduzidas de antígeno antes do congelamento. A invenção também se refere a uma vacina que pode ser obtida pelo método de acordo com a invenção e a uma composição contendo células dendríticas maduras, congeladas, introduzidas de antígeno.
BR0114030-2A 2000-08-24 2001-08-24 Método para preparação de células dendrìticas maduras, crioconservadas, prontas para uso, introduzidas ou não com antìgenos BR0114030A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10041515A DE10041515A1 (de) 2000-08-24 2000-08-24 Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
PCT/EP2001/009790 WO2002016560A1 (de) 2000-08-24 2001-08-24 Verfahren zur herstellung gebrauchsfertiger, antigenbeladener oder -unbeladener, kryokonservierter, reifer dendritischer zellen

Publications (1)

Publication Number Publication Date
BR0114030A true BR0114030A (pt) 2003-09-23

Family

ID=7653599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114030-2A BR0114030A (pt) 2000-08-24 2001-08-24 Método para preparação de células dendrìticas maduras, crioconservadas, prontas para uso, introduzidas ou não com antìgenos

Country Status (14)

Country Link
US (2) US8236562B2 (pt)
EP (1) EP1311658B1 (pt)
JP (1) JP4610847B2 (pt)
KR (1) KR100849740B1 (pt)
CN (1) CN1471575A (pt)
AT (1) ATE411380T1 (pt)
AU (2) AU8212301A (pt)
BR (1) BR0114030A (pt)
CA (1) CA2420260A1 (pt)
DE (2) DE10041515A1 (pt)
DK (1) DK1311658T3 (pt)
NZ (1) NZ524356A (pt)
WO (1) WO2002016560A1 (pt)
ZA (1) ZA200301466B (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US7566568B2 (en) * 2001-04-27 2009-07-28 Istituto Superiore Di Sanita Method for generating highly active human dendritic cells from peripheral blood mononuclear cells
AU2003258081A1 (en) * 2002-08-02 2004-02-23 South Alabama Medical Sciences Foundation Cancer vaccines containing epitopes of oncofetal antigen
WO2005073366A1 (en) * 2004-01-30 2005-08-11 Lifecord Inc. Method for isolating and culturing multipotent progenitor/stem cells from umbilical cord blood and method for inducing differentiation thereof
ES2357606T3 (es) 2004-04-15 2011-04-28 Athera Biotechnologies Ab Anticuerpos contra conjugados de fosforilcolina.
EP1767216B1 (en) 2004-06-11 2012-07-11 Riken Drug having regulatory cell ligand contained in liposome
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
DE602005025005D1 (de) 2004-10-07 2011-01-05 Argos Therapeutics Inc Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
KR20170086700A (ko) 2005-04-08 2017-07-26 아르고스 쎄라퓨틱스 인코포레이티드 수지상 세포 조성물 및 방법
EP2037957A4 (en) * 2006-06-30 2010-09-08 Baylor Res Inst USING GM-CSF AND INTERFERON ALPHA PRODUCED AND DENDRITIC CELLS LOADED WITH HEAT-TREATED AND DEFECTED CANCER CELLS
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
SI2484375T1 (en) 2006-09-26 2018-08-31 Infectious Disease Research Institute A vaccine composition comprising a synthetic adjuvant
WO2009062001A1 (en) * 2007-11-08 2009-05-14 Dana-Farber Cancer Institute, Inc. Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28
WO2010141861A1 (en) 2009-06-05 2010-12-09 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
US20130052211A1 (en) * 2009-07-09 2013-02-28 South Alabama Medical Science Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof
EP2547360A4 (en) * 2010-03-15 2013-11-20 Univ Pennsylvania SYSTEM AND METHOD FOR THE PRODUCTION AND STORAGE OF ACTIVATED TIRES OF DENDRITIC CELLS
HUE026885T2 (en) 2010-03-31 2016-08-29 Stabilitech Ltd Stabilize virus fragments
WO2011121301A1 (en) 2010-03-31 2011-10-06 Stabilitech Ltd Excipients for stabilising viral particles, polypeptides or biological material
EP2552410B1 (en) 2010-03-31 2018-10-24 Stabilitech Biopharma Ltd Method for preserving alum adjuvants and alum-adjuvanted vaccines
WO2011140284A2 (en) * 2010-05-04 2011-11-10 Fred Hutchinson Cancer Research Center Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CA2843960C (en) 2011-08-09 2020-09-15 Athera Biotechnologies Ab Antibodies binding to phosphorylcholine (pc) and/or pc conjugates
HUE045163T2 (hu) 2011-08-09 2019-12-30 Athera Biotechnologies Ab Új ellenanyagok foszforilkolin ellen
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
RU2486238C1 (ru) * 2011-12-29 2013-06-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО СибГМУ Минздравсоцразвития России) СПОСОБ НАГРУЗКИ ДЕНДРИТНЫХ КЛЕТОК АНТИГЕНОМ ИНФЕКЦИОННОГО ПРОИСХОЖДЕНИЯ Opisthorchis felineus
AU2013262691B2 (en) 2012-05-16 2018-12-20 Immune Design Corp. Vaccines for HSV-2
NL2009102C2 (en) * 2012-07-02 2014-01-06 Dcprime B V Method for dc-loading.
AU2014253791B2 (en) 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
AU2017201074A1 (en) * 2014-07-17 2017-03-16 The Trustees Of The University Of Pennsylvania Manufacturing of multi-dose injection ready dendritic cell vaccines, combination therapies for blocking HER2 and HER3, and estrogen receptor positive HER2 breast cancer therapy
CA2986687A1 (en) * 2015-05-22 2016-12-01 Brian J. Czerniecki Manufacturing multi-dose injection ready dendritic cell vaccines
AU2016304853C1 (en) * 2015-08-11 2023-03-16 Orbis Health Solutions Llc Bacterial and viral vaccine strategy
EP3364985A4 (en) 2015-10-19 2019-03-27 University Of Maryland, Baltimore METHOD FOR GENERATING MANIPULATED DENDRITIC CELL LINES FROM HUMAN PRIMARY BLOOD
JP6903866B2 (ja) * 2016-01-27 2021-07-14 国立大学法人 熊本大学 血液由来単球の増殖誘導方法
CN108934158B (zh) * 2016-02-01 2022-11-15 Gc细胞治疗 细胞冻存用培养基组合物及其应用
US11020465B2 (en) 2016-03-04 2021-06-01 The Trustees Of Columbia University In The City Of New York Development of dual whole cell-based vaccine against pancreatic cancer
CN105797146A (zh) * 2016-03-11 2016-07-27 高贵 一种特异性抗原发性肝癌免疫树状突细胞疫苗及其体外制备方法
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
EP3456343A1 (en) 2017-08-09 2019-03-20 Dodge Private Equity Ltd. Vaccine formulation of dendritic cells
CA3081616A1 (en) 2017-11-07 2019-05-16 Coimmune, Inc. Methods and uses for dendritic cell therapy
JP7397493B2 (ja) 2018-06-21 2023-12-13 ユニベルシテイト ゲント 治療用途のための樹状細胞のｉｎ ｖｉｔｒｏ分化および成熟のための方法
CN110637810A (zh) * 2019-10-18 2020-01-03 中生康元生物科技(北京)有限公司 一种临床级树突状细胞冻存液
EP4093195A1 (en) * 2020-01-21 2022-11-30 Takeda Pharmaceutical Company Limited Compositions and methods of cryopreserving cells
WO2022061811A1 (zh) * 2020-09-27 2022-03-31 深圳华大生命科学研究院 药物组合物及其制备方法和应用
CN112852732A (zh) * 2021-03-09 2021-05-28 四川省人民医院 Dc细胞培养方法、培养基和基于dc治疗策略的药物及酪氨酸激酶抑制剂在制备其的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308626A (en) * 1985-06-28 1994-05-03 Toni N. Mariani Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
US5622867A (en) * 1994-10-19 1997-04-22 Lifecell Corporation Prolonged preservation of blood platelets
AU4106796A (en) * 1994-11-09 1996-06-06 Federico Castro Munozledo Wound repair dressings and methods for their preservation
US6010905A (en) 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US5580714A (en) * 1995-03-08 1996-12-03 Celox Laboratories, Inc. Cryopreservation solution
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
FR2746109B1 (fr) * 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
JPH10323944A (ja) 1997-05-23 1998-12-08 Tokuyama Corp 離型フィルム
US6274378B1 (en) 1997-10-27 2001-08-14 The Rockefeller University Methods and compositions for obtaining mature dendritic cells
WO1999046984A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Compositions and methods for the frozen storage of dendritic cells
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
EP1117679B9 (en) * 1998-10-02 2010-07-07 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
JP2000143534A (ja) * 1998-11-13 2000-05-23 Asahi Chem Ind Co Ltd 樹状細胞ワクチン及びその製造方法
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen

Also Published As

Publication number Publication date
NZ524356A (en) 2004-07-30
KR20030061782A (ko) 2003-07-22
JP2004507238A (ja) 2004-03-11
KR100849740B1 (ko) 2008-08-01
ATE411380T1 (de) 2008-10-15
DK1311658T3 (da) 2009-01-12
EP1311658A1 (de) 2003-05-21
US8574901B2 (en) 2013-11-05
AU8212301A (en) 2002-03-04
US20040253574A1 (en) 2004-12-16
AU2001282123B2 (en) 2008-02-28
DE10041515A1 (de) 2002-03-14
WO2002016560A1 (de) 2002-02-28
DE50114426D1 (de) 2008-11-27
US20120301959A1 (en) 2012-11-29
CA2420260A1 (en) 2003-02-21
AU2001282123B8 (en) 2008-04-03
CN1471575A (zh) 2004-01-28
US8236562B2 (en) 2012-08-07
JP4610847B2 (ja) 2011-01-12
ZA200301466B (en) 2004-02-24
EP1311658B1 (de) 2008-10-15

Similar Documents

Publication Publication Date Title
BR0114030A (pt) Método para preparação de células dendrìticas maduras, crioconservadas, prontas para uso, introduzidas ou não com antìgenos
CN104145943B (zh) 一种人脐带华通氏胶组织的冻存保护液及其制备与应用
Robertson Some features of the calcium metabolism of the shore crab (Carcinus maenas Pennant)
Matsubara et al. Course of proteolytic cleavage in three classes of yolk proteins during oocyte maturation in barfin flounder Verasper moseri, a marine teleost spawning pelagic eggs
NO20074278L (no) Tigecyklinblandinger og fremgangsmater for fremstilling
IL72740A (en) Adjuvant compositions comprising polyoxypropylene-polyoxyethylene block polymers,vaccine compositions containing them and methods for enhancing the immunogenicity of antigens
BR0015224A (pt) Anticorpo anti-antìgeno de célula estaminal prostática (psca) isolado, anticorpo monoclonal anti-psca, ácido nucleico isolado, vetor de expressão, célula, célula hospedeira, método de produção de anticorpo, composição método in vitro para matar uma célula cancerosa que expresse psca, uso de uma anticorpo monoclonal anti-psca e artigo industrializado
BR0014438A (pt) Formulação para mulheres na menopausa
DE3852761T3 (de) Saponin-hilfsmittel.
HK1075267A1 (en) Dye mixtures of fiber-reactive azo dyes, their production and use
BR0010323A (pt) Composições imunogênicas, kit e método de confecção da mesma para uso na imunização de um mamìfero
ATE413862T1 (de) Stabilisierte natürliche cannabinoid formulierung
AR122060A1 (es) Formulaciones de anticuerpos anti-il-33 y métodos de uso de las mismas
BR0110474A (pt) Métodos para remover células neoplásticas mediadas por ras de uma composição celular, para preparar uma composição celular para transplante em um receptor e para reduzir um risco de recorrência de tumor, e, composição celular
DE60226896D1 (de) Herstellung von f(ab')2 fragmenten in saügetierzelle
LeMevel et al. A Microassay for the Quantitation of Cytotoxic Antitumor Antibody: Use of 125I-Iododeoxyuridine as a Tumor Cell Labell
EP1276379A4 (en) GROWTH, FREEZING AND TESTING (IN SITU) OF CULTURE CELLS
WO2005056763A3 (en) Process and formulation to improve viability of stored cells and tissue
WO2004101737A3 (en) A novel adjuvant capable of specifically activating the adaptive immune response
DE602004028233D1 (de) Klonierverfahren bei der ratte mittels zellkerntransfer
ATE355078T1 (de) Untereiheitsimpfstoffe und verfahren zur deren herstellung
Peek et al. The measurement of human endometrial prostaglandin production a comparison of two in vitro methods
Luk'yanenko et al. Heterogeneity and polymorphism of functionally specialized blood proteins in migratory fish: The case study of the North Caspian population of the Russian sturgeon during sea and river periods of life. 1. Albumins
ATE283909T1 (de) Verfahren zur herstellung von waschmittelgranulaten
UA155130U (uk) Спосіб кріоконсервування фрагментів пуповини людини

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O ART .8O COMBINADO COM ART. 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.

B15K Others concerning applications: alteration of classification

Ipc: C12N 5/0784 (2010.01), A61K 39/00 (2006.01)